Expert consensus on multidisciplinary collaboration in perioperative immunotherapy for hepatocellular carcinoma (2025 edition)

作者：Zeyang Ding, Chaoyi Yuan, Ying Zhu, Hong Wu, Haisu Dai, Jiabei Wang, Minghao Sun, Decai Yu, Feng Xia, Kui Wang, Yan He, Shao‐Lai Zhou, Yangxun Pan, Lin‐Lin Shen, Qiang Wang, Jiali Huo, Bangde Xiang, Yilei Mao, Leida Zhang, Ledu Zhou, Xiao Liang, Minshan Chen, Min Chen, Lianxin Liu, Ming Kuang, Jian Zhou, Jia Fan, Jiahong Dong, Xiaoping Chen, Lun–Xiu Qin, Bixiang Zhang · 发表于：Oncology and Translational Medicine · 年份：2025 · DOI：10.1097/ot9.0000000000000122 · 被引用次数：1 · 研究领域：Cancer Immunotherapy and Biomarkers、Hepatocellular Carcinoma Treatment and Prognosis、Pancreatic and Hepatic Oncology Research

Abstract Immune checkpoint inhibitors (ICIs) have led to substantial advances in immunotherapy for hepatocellular carcinoma (HCC). Moreover, the use of ICI-based combination regimens for perioperative management of HCC has increased. To support clinicians in the rational, effective, and safe use of perioperative immunotherapy, the Hepatobiliary and Pancreatic Multidisciplinary Team Committee of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association, the Hepatic Surgery Group of the Surgery Branch of the Chinese Medical Association, the General Surgery Branch of the Chinese Society of Geriatric Medicine, and the Editorial Board of Chinese Journal of Digestive Surgery convened a multidisciplinary expert panel to develop the Chinese Multidisciplinary Expert Consensus on Perioperative Immunotherapy for Hepatocellular Carcinoma (2025 Edition). This consensus focuses on the principles and clinical applications of ICI-based immunotherapy in the perioperative setting for HCC. Accordingly, this review summarizes clinical recommendations based on the latest research to guide healthcare professionals involved in HCC management.